|
Event
|
PBO + BAP 0.5 (n = 39)
|
BAP 0.5 + BAP 0.5 (n = 66)
|
PBO + BAP 1.0 (n = 37)
|
BAP 1.0 + BAP 1.0 (n = 56)
|
|---|
|
ARIA-E (vasogenic cerebral edema)
|
3 (7.7)
|
2 (3.0)
|
6 (16.2)
|
3 (5.4)
|
|
Urinary tract infection
|
2 (5.1)
|
7 (10.6)
|
1 (2.7)
|
0
|
|
Headache
|
1 (2.6)
|
1 (1.5)
|
3 (8.1)
|
2 (3.6)
|
|
Gastroenteritis
|
0
|
0
|
3 (8.1)
|
0
|
|
Nasopharyngitis
|
3 (7.7)
|
1 (1.5)
|
1 (2.7)
|
2 (3.6)
|
|
Delusion
|
3 (7.7)
|
3 (4.5)
|
0
|
0
|
|
Gait disturbance
|
3 (7.7)
|
0
|
1 (2.7)
|
0
|
|
Fall
|
0
|
3 (4.5)
|
2 (5.4)
|
4 (7.1)
|
|
Dizziness
|
1 (2.6)
|
4 (6.1)
|
0
|
0
|
|
Cerebral microhemorrhage
|
0
|
1 (1.5)
|
0
|
3 (5.4)
|
|
Cognitive disorder
|
1 (2.6)
|
2 (3.0)
|
2 (5.4)
|
3 (5.4)
|
|
Depression
|
0
|
0
|
2 (5.4)
|
0
|
|
Subdural hematoma
|
0
|
0
|
0
|
3 (5.4)
|
|
Aggression
|
2 (5.1)
|
0
|
0
|
0
|
|
Anemia
|
2 (5.1)
|
1 (1.5)
|
0
|
0
|
|
Cough
|
2 (5.1)
|
0
|
0
|
2 (3.6)
|
|
Nausea
|
2 (5.1)
|
0
|
0
|
0
|
- Data presented as n (%)
-
ARIA-E amyloid-related imaging abnormalities with edema or effusions, BAP bapineuzumab, PBO placebo
